Company intelligence / Profile preview

Olygose

Ownership: Private
Development stage: Commercial

Overview

Olygose develops and commercializes plant-based, lactose-free prebiotic fibers such as AlphaGOS®, which have demonstrated bifidogenic effects in both infants and adults. Their products are used to support gut health by increasing beneficial bacteria and modulating short-chain fatty acid production. Clinical studies have shown efficacy in improving gut flora balance and supporting weight management[2][3].

Therapeutic areas: GastroenterologyEndocrinologyMetabolic Disorders
Modalities: PrebioticNutraceutical
Industry: Food & Nutrition

Drug pipeline

3 assets

AlphaGOS

Commercial

Indications: Digestive health, Gut microbiota modulation

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Olygose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olygose.

Explore the full profile